Company: ZVRA
Filing Date: 2025-04-24
Form Type: PRRN14A
Source: 0000897069-25-000871
Chunk: 19

Company: ZEVRA THERAPEUTICS, INC.
Filing Date: 2025-04-24
Form: PRRN14A
Chunk 19
---
 accordance with its practice at the time. The Proponent does not expect that any of the Nominees will be unable to stand for election, but, in the event any Nominee is unable to serve or for good cause will not serve, the shares of Common Stock represented by the enclosed BLUEuniversal proxy card marked to vote “ FOR” the Nominees, or if the card is signed and returned but no direction is indicated, will be voted for substitute nominee(s), to the extent this is not prohibited under the Amended and Restated Bylaws of the Company (the “ Bylaws”) and applicable law. In addition, the Proponent reserves the right to nominate substitute person(s) if the Company makes or announces any changes to the Bylaws or takes or announces any other action that has, or if consummated would have, the effect of disqualifying any Nominee, to the extent this is not prohibited under the Bylaws and applicable law. In any such case, shares of Common Stock represented by the enclosed BLUEuniversal proxy card marked to vote “ FOR” the Nominees, or if the card is signed and returned no direction is indicated, will be voted for such substitute nominee(s). Approval of Proposal 1 for the Election of Directors. The election of directors requires the affirmative vote of a plurality of the shares of Common Stock present in person or by proxy and entitled to vote at the Annual Meeting. A “plurality” means that the individuals who receive the largest number of affirmative votes cast are elected as directors up to the maximum number of directors to be chosen at the Annual Meeting. Abstentions are not applicable; and broker non-votes will not have any effect on the outcome of the Proposal 1 for the election of directors. THE PROPONENT URGES YOU TO VOTE “FOR” THE ELECTION OF MESSRS. TRAVIS C. MICKLE, PHD AND ARTHUR C. REGAN ON THE ENCLOSED BLUEUNIVERSAL PROXY CARD. 12 PROPOSAL 2 RATIFICATION OF APPOINTMENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM As discussed in further detail in the Company’s proxy statement, the Audit Committee has selected Ernst & Young LLP (“ EY”) as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2025 and has further directed that the Board submit the appointment of its independent registered public accounting firm for ratification by the stockholders at the Annual Meeting. EY has served